NACI added that anyone above 6 months of age who isn't considered high risk "may receive the most recently updated vaccine in ...

Jim Cramer’s 10 Best Stock Picks for Investors Right Now. In this article, we are going to take a look at where Moderna, Inc.

Moderna shares are moving higher on Tuesday after the company announced that Health Canada approved its updated COVID-19 ...

Moderna, once a shining star in the pharmaceutical industry for its rapid development of COVID-19 vaccines, is now facing a ...

After raking in a vaccine windfall during the pandemic, Moderna has hemorrhaged money to develop its mRNA technology. (Adam Glanzman/Bloomberg News) Moderna is under pressure to deliver significant ...

Moderna pushed back its break-even goal by two years on Thursday as it delayed the timeline for developing several key ...

As part of a broad restructuring, the company revealed plans to reduce research spending by 20% over the next few years and ax five programs in early development. It won’t cut jobs, however, a ...

Moderna stock is plunging Thursday after the COVID-19 vaccine maker announced plans to drastically cut its R&D spending to ...

Moderna’s stock has seen an extended downtrend since peaking above $480 in late 2021. After crashing to below $70 in November last year, the stock experienced a strong medium-term rally that took it ...

Moderna has vowed to cut annual R&D spending by $1.1 billion by 2027. The decision to shrink the budget by more than 20% follows commercial setbacks that have persuaded the biotech to take a “more ...

Also on Thursday, Moderna announced positive late-stage trial results on its vaccine against respiratory syncytial virus in high-risk adults ages 18 to 59, with plans to file for approval for that age ...

COVID-19 numbers are on the rise across the state of Indiana, and few Hoosiers are up to date on their vaccinations for the ...